ONCAlert | 2018 ASCO Annual Meeting

Lung Cancer MORE >>

According to findings from the phase III IMpower132 study, the addition of atezolizumab to pemetrexed and cisplatin or carboplatin reduced the risk of disease progression or death compared with chemotherapy alone in patients with advanced nonsquamous non–small cell lung cancer.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.